肝细胞癌患者接受索拉非尼治疗的完全缓解:与皮肤不良事件的关系
该回顾性队列研究由西班牙10个中心提交索拉非尼治疗肝细胞癌后完全缓解的病例,中心化复核影像后确认12例完全缓解者,占1119例患者的1%。完全缓解者中除1例外均出现早期皮肤反应,中位总生存期85.8个月,中位治疗持续时间40.1个月。
要点
- 索拉非尼治疗的肝细胞癌患者中完全缓解率约为1%(12/1119)。
- 完全缓解者中11例出现早期皮肤不良反应,支持免疫/炎症特征与疗效相关。
- 完全缓解者中位总生存期85.8个月,中位治疗持续时间40.1个月。
核心结论
- 完全缓解影响约1%接受索拉非尼治疗的肝细胞癌患者。
- 完全缓解与早期皮肤不良反应的关联支持特定免疫/炎症患者特征在索拉非尼更好应答中的作用。
研究设计与样本
- 回顾性队列研究,西班牙10个中心提交索拉非尼治疗肝细胞癌后完全缓解的病例。
- 共纳入1119例接受索拉非尼治疗的肝细胞癌患者,中心化复核治疗前、首次对照、治疗后及完全缓解时和停药后至少1个月的影像。
主要发现
- 1119例患者中20例被各中心分类为完全缓解者,中心化复核后排除8例。
- 12例被分类为完全缓解者(58%丙型肝炎病毒阳性,中位年龄59.7岁,83.4% Child-Pugh A级,91.7% Eastern Cooperative Oncology Group体能状态0,83.3% Barcelona Clinic Liver Cancer C期)。
- 10例患者所有肿瘤部位完全消失,2例仅残留小纤维化瘢痕。
- 完全缓解者中位总生存期85.8个月,中位治疗持续时间40.1个月。
- 除1例外所有完全缓解者出现早期皮肤不良反应;7例在达到完全缓解后因不良事件、患者决定或肝失代偿停用索拉非尼。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The clinical benefit of sorafenib in patients with hepatocellular carcinoma (HCC) has been undervalued due to the absence of complete responses, even though patients who develop early dermatologic reactions have shown to have a positive outcome. In addition, sorafenib is described as an antiangiogenic drug, but it also acts on immunological cells. Thus, the goal of this study was to assess the complete response rate in a retrospective cohort of HCC patients treated with sorafenib and to describe the profile of the patients who achieve complete response for identifying factors related to this event and their connection with the immunological profile of sorafenib. Ten Spanish centers submitted cases of complete response under sorafenib. The baseline characteristics, development of early dermatologic reactions, and cause of treatment discontinuation were annotated. Radiological images taken before starting sorafenib, at first control, after starting sorafenib, at the time of complete response, and at least 1 month after treatment were centrally reviewed. Of the 1119 patients studied, 20 had been classified as complete responders by the centers, but eight of these patients were excluded after central review. Ten patients had complete disappearance of all tumor sites, and two had just a small residual fibrotic scar. Thus, 12 patients were classified as complete responders (58% HCV, median age 59.7 years, 83.4% Child-Pugh class A, Eastern Cooperative Oncology Group performance status 0 91.7%, and Barcelona Clinic Liver Cancer stage C 83.3%). The median overall survival and treatment duration were 85.8 and 40.1 months, respectively. All but one patient developed early dermatologic reactions, and seven patients discontinued sorafenib after achieving complete response due to adverse events, patient decision, or liver decompensation. Conclusion: Complete response affects 1% of patients with HCC who are treated with sorafenib. The association of complete response with early dermatologic reactions supports the role of a specific immune/inflammatory patient profile in the improved response to sorafenib. (Hepatology 2018;67:612-622).
引用
- Rimola J, Díaz-González Á, Darnell A, et al. Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events. Hepatology. 2018. PMID: 28898447. doi:10.1002/hep.29515
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。